Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Could Gut Microbiota Be the “New Key” to Functional Cure in Chronic Hepatitis B?

    Study Overview The study included 70 HBeAg-negative CHB patients, who were categorized into three groups based on HBV DNA levels. The FC group (n=18) had undetectable HBV DNA and HBsAg.…

    2025.03.06
  • Dr. Junping Shi Leads China’s First Liver Biopsy-Based RCT (VENS Study) Confirming Vitamin E’s Safety & Efficacy in MASH

    To explore this possibility, Dr. Junping Shi from the Affiliated Hospital of Hangzhou Normal University led a nationwide, multi-center, large-sample, randomized, double-blind, placebo-controlled clinical trial known as the VENS study…

    2025.03.06
  • At the EHA (European Hematology Association) congress, I witnessed the intellectual collision in the field of hematology. Scholars shared their research findings from the podium, with each presentation being a spark of knowledge and wisdom.

    At the EHA (European Hematology Association) congress, I witnessed the intellectual collision in the field of hematology. Scholars shared their research findings from the podium, with each presentation being a…

    2025.03.05
  • At the European Hematology Association (EHA) congress , Professor Richard Van Wijk from the University Medical Center Utrecht delivered a captivating presentation titled “Activation of pyruvate kinase as a therapeutic option for rare hemolytic anemias.”

    At the European Hematology Association (EHA) congress , Professor Richard Van Wijk from the University Medical Center Utrecht delivered a captivating presentation titled “Activation of pyruvate kinase as a therapeutic option for rare hemolytic anemias.” His insightful discussion on the potential of pyruvate kinase activation in treating these rare conditions has sparked significant interest among…

    2025.03.05
  • From across the globe, distinguished researchers are presenting their findings at the European Hematology Association (EHA) Congress, illuminating new pathways in hematology.

    2025.03.05
  • Renowned international scholars gather at the European Hematology Association (EHA) Congress, sharing groundbreaking insights and fostering global collaboration in the field of hematology.

    2025.03.05
  • Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion

    The primary aim is to understand the characteristics, diagnosis, treatment, and prognosis of isolated extramedullary relapse (IEMR)  in AML patients post-allo-HSCT, with a specific focus on cardiac involvement. A 35-year-old…

    2025.03.05
  • EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL: First-In-Human, Phase 1 Study

    Study Overview Background Relapsed/refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) lacks effective salvage therapies and has poor prognosis. Recently, CD7-targeted CAR-T cell therapy has shown efficacy in r/r T-ALL, but…

    2025.03.05
«previous next»
Recent Posts
  • CSCO 2026 Debate | Professors Wenyan Chen and Tengfei Chao: Should Immunotherapy Be Combined with Chemotherapy or an ADC in First-Line Treatment of Advanced TNBC?
  • CSCO 2026 | Professor Hong Bu: Standardizing Breast Pathology Diagnosis Requires “Knowing, Understanding, and Applying the Standards,” While Digital and Intelligent Transformation Must Address Clinical Pain Points
  • CSCO 2026 | Professor Chunfang Hao: ADCs Are Expanding Across the Breast Cancer Treatment Continuum, Advancing From Later Lines to First-Line Therapy and From Monotherapy to Combination Regimens
  • CSCO 2026 | Professor Yanxia Shi: Early Intervention Guided by ctDNA and Dual-Target ADC Innovation Are Reshaping Precision Breast Cancer Treatment
  • CSCO 2026 | Professor Yongmei Yin: OptiTROP-Breast05 Wins the “2026 Innovation Research Award,” as China’s First Homegrown TROP2 ADC Advances First-Line TNBC Treatment
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top